Compass Therapeutics/CMPX

-
-
1D1W1MYTD1YMAX

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

Ticker

CMPX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Vered Bisker-Leib

Employees

32

Headquarters

Boston, United States
Website
www.compasstherapeutics.com

CMPX Metrics

BasicAdvanced
US$220M
Market cap
-
P/E ratio
-US$0.35
EPS
-
Beta
-
Dividend rate
US$220M
US$3.62
US$1.15
353K
40.743
-26.03%
-27.35%
-27.21%
1.402
1.402
3.23%

What the Analysts think about CMPX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
451.88% upside
High US$10.00
Low US$7.00
US$1.60
Current price
US$8.83
Average price target

CMPX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$0
NaN%
Net income
-US$11M
-20.15%
Profit margin
0%
NaN%

CMPX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 29.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.09
-US$0.08
-US$0.11
-US$0.08
-
Expected
-US$0.08
-US$0.11
-US$0.09
-US$0.11
-US$0.11
Surprise
10.53%
-25.33%
16.84%
-29.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Compass Therapeutics stock?

Compass Therapeutics (CMPX) has a market cap of $220M as of May 20, 2024.

What is the P/E ratio for Compass Therapeutics stock?

The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of May 20, 2024.

Does Compass Therapeutics stock pay dividends?

No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Compass Therapeutics dividend payment date?

Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Therapeutics?

Compass Therapeutics (CMPX) does not currently have a Beta indicator.

What is the Compass Therapeutics stock price target?

The target price for Compass Therapeutics (CMPX) stock is $8.83, which is 451.88% above the current price of $1.6. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Compass Therapeutics stock

Buy or sell Compass Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing